Drug
NMDAE
NMDAE is a pharmaceutical drug with 7 clinical trials. Currently 7 active trials ongoing.
Total Trials
7
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
7(100%)
Phase Distribution
Ph phase_2
7
100%
Phase Distribution
0
Early Stage
7
Mid Stage
0
Late Stage
Phase Distribution7 total trials
Phase 2Efficacy & side effects
7(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
7
trials recruiting
Total Trials
7
all time
Status Distribution
Active(7)
Detailed Status
Recruiting7
Development Timeline
Analytics
Development Status
Total Trials
7
Active
7
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 27 (100.0%)
Trials by Status
recruiting7100%
Recent Activity
7 active trials
Showing 5 of 7
recruitingphase_2
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
NCT05052853
recruitingphase_2
Monotherapy of an NMDA Enhancer for Schizophrenia
NCT04745143
recruitingphase_2
Sex Differences in NMDA-enhancing Treatment of Schizophrenia
NCT07122895
recruitingphase_2
NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
NCT05136755
recruitingphase_2
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
NCT06021197
Clinical Trials (7)
Showing 7 of 7 trials
NCT05052853Phase 2
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
NCT04745143Phase 2
Monotherapy of an NMDA Enhancer for Schizophrenia
NCT07122895Phase 2
Sex Differences in NMDA-enhancing Treatment of Schizophrenia
NCT05136755Phase 2
NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
NCT06021197Phase 2
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
NCT04637620Phase 2
NMDA Modulation in Major Depressive Disorder
NCT05977023Phase 2
NMDA Receptor Modulation for the Treatment of Bipolar I Disorder
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7